298 related articles for article (PubMed ID: 33933805)
1. Molecular characteristics supporting l-Type amino acid transporter 1 (LAT1)-mediated translocation.
Kärkkäinen J; Laitinen T; Markowicz-Piasecka M; Montaser A; Lehtonen M; Rautio J; Gynther M; Poso A; Huttunen KM
Bioorg Chem; 2021 Jul; 112():104921. PubMed ID: 33933805
[TBL] [Abstract][Full Text] [Related]
2. Structural properties for selective and efficient l-type amino acid transporter 1 (LAT1) mediated cellular uptake.
Kärkkäinen J; Gynther M; Kokkola T; Petsalo A; Auriola S; Lahtela-Kakkonen M; Laine K; Rautio J; Huttunen KM
Int J Pharm; 2018 Jun; 544(1):91-99. PubMed ID: 29669256
[TBL] [Abstract][Full Text] [Related]
3. Insights into the Structure, Function, and Ligand Discovery of the Large Neutral Amino Acid Transporter 1, LAT1.
Singh N; Ecker GF
Int J Mol Sci; 2018 Apr; 19(5):. PubMed ID: 29695141
[TBL] [Abstract][Full Text] [Related]
4. Comparison of Experimental Strategies to Study l-Type Amino Acid Transporter 1 (LAT1) Utilization by Ligands.
Huttunen J; Agami M; Tampio J; Montaser AB; Huttunen KM
Molecules; 2021 Dec; 27(1):. PubMed ID: 35011270
[TBL] [Abstract][Full Text] [Related]
5. Characterization of the system L amino acid transporter in T24 human bladder carcinoma cells.
Kim DK; Kanai Y; Choi HW; Tangtrongsup S; Chairoungdua A; Babu E; Tachampa K; Anzai N; Iribe Y; Endou H
Biochim Biophys Acta; 2002 Sep; 1565(1):112-21. PubMed ID: 12225859
[TBL] [Abstract][Full Text] [Related]
6. Rigorous sampling of docking poses unveils binding hypothesis for the halogenated ligands of L-type Amino acid Transporter 1 (LAT1).
Singh N; Villoutreix BO; Ecker GF
Sci Rep; 2019 Oct; 9(1):15061. PubMed ID: 31636293
[TBL] [Abstract][Full Text] [Related]
7. Reevaluating the Substrate Specificity of the L-Type Amino Acid Transporter (LAT1).
Chien HC; Colas C; Finke K; Springer S; Stoner L; Zur AA; Venteicher B; Campbell J; Hall C; Flint A; Augustyn E; Hernandez C; Heeren N; Hansen L; Anthony A; Bauer J; Fotiadis D; Schlessinger A; Giacomini KM; Thomas AA
J Med Chem; 2018 Aug; 61(16):7358-7373. PubMed ID: 30048132
[TBL] [Abstract][Full Text] [Related]
8. Transport of amino acid-related compounds mediated by L-type amino acid transporter 1 (LAT1): insights into the mechanisms of substrate recognition.
Uchino H; Kanai Y; Kim DK; Wempe MF; Chairoungdua A; Morimoto E; Anders MW; Endou H
Mol Pharmacol; 2002 Apr; 61(4):729-37. PubMed ID: 11901210
[TBL] [Abstract][Full Text] [Related]
9. Secondary carbamate linker can facilitate the sustained release of dopamine from brain-targeted prodrug.
Thiele NA; Kärkkäinen J; Sloan KB; Rautio J; Huttunen KM
Bioorg Med Chem Lett; 2018 Sep; 28(17):2856-2860. PubMed ID: 30055889
[TBL] [Abstract][Full Text] [Related]
10. Structure-activity relations of leucine derivatives reveal critical moieties for cellular uptake and activation of mTORC1-mediated signaling.
Nagamori S; Wiriyasermkul P; Okuda S; Kojima N; Hari Y; Kiyonaka S; Mori Y; Tominaga H; Ohgaki R; Kanai Y
Amino Acids; 2016 Apr; 48(4):1045-1058. PubMed ID: 26724922
[TBL] [Abstract][Full Text] [Related]
11. L-type amino acid transporter 1 utilizing prodrugs of ferulic acid revealed structural features supporting the design of prodrugs for brain delivery.
Puris E; Gynther M; Huttunen J; Auriola S; Huttunen KM
Eur J Pharm Sci; 2019 Mar; 129():99-109. PubMed ID: 30625368
[TBL] [Abstract][Full Text] [Related]
12. L-type amino acid transporter 1 (LAT1): a new therapeutic target for canine mammary gland tumour.
Fukumoto S; Hanazono K; Komatsu T; Ueno H; Kadosawa T; Iwano H; Uchide T
Vet J; 2013 Oct; 198(1):164-9. PubMed ID: 23896327
[TBL] [Abstract][Full Text] [Related]
13. L-Type amino acid transporter 1 as a target for drug delivery.
Puris E; Gynther M; Auriola S; Huttunen KM
Pharm Res; 2020 May; 37(5):88. PubMed ID: 32377929
[TBL] [Abstract][Full Text] [Related]
14. L-Type amino acid transporter 1 (LAT1)-utilizing prodrugs are carrier-selective despite having low affinity for organic anion transporting polypeptides (OATPs).
Huttunen J; Gynther M; Vellonen KS; Huttunen KM
Int J Pharm; 2019 Nov; 571():118714. PubMed ID: 31610281
[TBL] [Abstract][Full Text] [Related]
15. Amino acid transporter LAT1 (SLC7A5) as a molecular target for cancer diagnosis and therapeutics.
Kanai Y
Pharmacol Ther; 2022 Feb; 230():107964. PubMed ID: 34390745
[TBL] [Abstract][Full Text] [Related]
16. Structure-activity relationship of a novel series of inhibitors for cancer type transporter L-type amino acid transporter 1 (LAT1).
Kongpracha P; Nagamori S; Wiriyasermkul P; Tanaka Y; Kaneda K; Okuda S; Ohgaki R; Kanai Y
J Pharmacol Sci; 2017 Feb; 133(2):96-102. PubMed ID: 28242177
[TBL] [Abstract][Full Text] [Related]
17. Amino acid ester prodrugs conjugated to the α-carboxylic acid group do not display affinity for the L-type amino acid transporter 1 (LAT1).
Rautio J; Kärkkäinen J; Huttunen KM; Gynther M
Eur J Pharm Sci; 2015 Jan; 66():36-40. PubMed ID: 25305508
[TBL] [Abstract][Full Text] [Related]
18. Hemocompatible LAT1-inhibitor can induce apoptosis in cancer cells without affecting brain amino acid homeostasis.
Markowicz-Piasecka M; Huttunen J; Montaser A; Huttunen KM
Apoptosis; 2020 Jun; 25(5-6):426-440. PubMed ID: 32405891
[TBL] [Abstract][Full Text] [Related]
19. A new treatment for human malignant melanoma targeting L-type amino acid transporter 1 (LAT1): a pilot study in a canine model.
Fukumoto S; Hanazono K; Fu DR; Endo Y; Kadosawa T; Iwano H; Uchide T
Biochem Biophys Res Commun; 2013 Sep; 439(1):103-8. PubMed ID: 23954667
[TBL] [Abstract][Full Text] [Related]
20. Role of l-Type Amino Acid Transporter 1 at the Inner Blood-Retinal Barrier in the Blood-to-Retina Transport of Gabapentin.
Akanuma SI; Yamakoshi A; Sugouchi T; Kubo Y; Hartz AMS; Bauer B; Hosoya KI
Mol Pharm; 2018 Jun; 15(6):2327-2337. PubMed ID: 29688723
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
